on June 5, 2013 |
Permalink
| Comments (1)
Topics: Cardiovascular, Service Lines, Business Development, Strategy, Technology Assessment, Planning, Service Line Growth, Volume Growth
Brian Contos and Megan Tooley, Cardiovascular Roundtable
On behalf of the Cardiovascular Roundtable, we are excited to share early results from our analysis of transcatheter aortic valve replacement (TAVR) cases from the just-released Medicare claims data for the 2012 fiscal year (Oct. 1, 2011 – Sept. 30, 2012). To the best of our knowledge, ours is the first analysis of all U.S. TAVR procedures performed in the year following FDA approval.
These analyses address a number of questions we’ve received from members regarding the TAVR marketplace and experiences from early adopters, including volumes, patient characteristics, clinical outcomes, and reimbursement.
Continue reading:
New transcatheter valve benchmarks you won't find anywhere else
on May 8, 2013 |
Permalink
Topics: Cardiovascular, Service Lines, Business Development, Strategy, Technology Assessment, Planning
Megan Tooley, Cardiovascular Roundtable
The decision to pursue transcatheter aortic valve replacement (TAVR) should not be taken lightly—we’ve been helping walk members through the considerations in our recent publication Blueprint for Valve Centers, executive summary webconference, and recent coverage in Cardiovascular Rounds.
But for some progressive institutions, TAVR is the right choice both to fill a clinical need in the community, as well as grow the CV program. So once you’ve made that decision, where do you go from there?
For a quick primer on the top investments to consider when starting a program, we turned to CV leaders at Exempla Saint Joseph Hospital, a 384-bed hospital in Denver, Colorado, who successfully launched a TAVR program last fall.
Read on for three key pieces of advice Saint Joseph Hospital has for institutions looking to launch their own TAVR program.
Continue reading:
You've decided to launch a TAVR program...now what?
on January 14, 2013 |
Permalink
Topics: Cardiovascular, Service Lines, Cardiac Cath, Cardiac Surgery, Regionalization and Networks, Strategy, Service Line Growth, Volume Growth, Technology Assessment, Planning, Program Infrastructure, Business Development
Megan Tooley, Cardiovascular Roundtable
There is no question the emergence of transcatheter valve technologies—specifically transcatheter aortic valve replacement (TAVR)—has elicited unprecedented excitement from the cardiovascular community in recent years. However, despite this enthusiasm, the reality is only a portion of hospitals will meet the strict resource and volume requirements necessary to become TAVR sites in the near future.
This may leave many of you wondering, “So what if we’re not a TAVR program? Is there still a place for us in the valve market?” You’re not alone, and as we explore in our national meeting series, your options for treating valve disease and disorders do not end at TAVR.
Learn how one Roundtable member is ensuring their patients have access to a full range of valve services—even if they’re not the TAVR program.
Continue reading:
So you're not a TAVR program—Now what?
